Limits...
BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries.

Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, Ruijter Hd, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S - Eur. J. Epidemiol. (2014)

Bottom Line: BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries.Results from this study will contribute to improved cardiovascular risk prediction across different European populations.The present publication describes the rationale and design of the BiomarCaRE project.

View Article: PubMed Central - PubMed

Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.

ABSTRACT
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.

Show MeSH

Related in: MedlinePlus

Overview of data analyses performed in phases 1 and 2 of BiomarCaRE
© Copyright Policy - OpenAccess
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4197377&req=5

Fig4: Overview of data analyses performed in phases 1 and 2 of BiomarCaRE

Mentions: BiomarCaRE comprises two closely interacting data centres: one centre that is responsible for the analyses of all population-derived biomarkers which is based at the National Institute for Health and Welfare (THL) in Helsinki; Finland. This data centre has a long-standing and unparalleled experience of epidemiological data harmonization and central data management and analyses of the MORGAM Project [9] and its predecessor, the WHO MONICA Project (Tunstall-Pedoe and Project [32]. The second data centre is based at the University at Lübeck, Germany and is responsible for the analyses of biomarkers derived from the diseased cohorts. Data obtained in clinical trial repositories will be analysed directly at the respective partner site. Figure 4 illustrates and summarizes analyses performed in phases 1 and 2.Fig. 4


BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries.

Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, Ruijter Hd, Schnabel RB, Kee F, Salomaa V, Siebert U, Thorand B, Ziegler A, Breek H, Pasterkamp G, Kuulasmaa K, Koenig W, Blankenberg S - Eur. J. Epidemiol. (2014)

Overview of data analyses performed in phases 1 and 2 of BiomarCaRE
© Copyright Policy - OpenAccess
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4197377&req=5

Fig4: Overview of data analyses performed in phases 1 and 2 of BiomarCaRE
Mentions: BiomarCaRE comprises two closely interacting data centres: one centre that is responsible for the analyses of all population-derived biomarkers which is based at the National Institute for Health and Welfare (THL) in Helsinki; Finland. This data centre has a long-standing and unparalleled experience of epidemiological data harmonization and central data management and analyses of the MORGAM Project [9] and its predecessor, the WHO MONICA Project (Tunstall-Pedoe and Project [32]. The second data centre is based at the University at Lübeck, Germany and is responsible for the analyses of biomarkers derived from the diseased cohorts. Data obtained in clinical trial repositories will be analysed directly at the respective partner site. Figure 4 illustrates and summarizes analyses performed in phases 1 and 2.Fig. 4

Bottom Line: BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries.Results from this study will contribute to improved cardiovascular risk prediction across different European populations.The present publication describes the rationale and design of the BiomarCaRE project.

View Article: PubMed Central - PubMed

Affiliation: Clinic for General and Interventional Cardiology, University Heart Centre Hamburg, Martinistr. 52, 20246, Hamburg, Germany, t.zeller@uke.de.

ABSTRACT
Biomarkers are considered as tools to enhance cardiovascular risk estimation. However, the value of biomarkers on risk estimation beyond European risk scores, their comparative impact among different European regions and their role towards personalised medicine remains uncertain. Biomarker for Cardiovascular Risk Assessment in Europe (BiomarCaRE) is an European collaborative research project with the primary objective to assess the value of established and emerging biomarkers for cardiovascular risk prediction. BiomarCaRE integrates clinical and epidemiological biomarker research and commercial enterprises throughout Europe to combine innovation in biomarker discovery for cardiovascular disease prediction with consecutive validation of biomarker effectiveness in large, well-defined primary and secondary prevention cohorts including over 300,000 participants from 13 European countries. Results from this study will contribute to improved cardiovascular risk prediction across different European populations. The present publication describes the rationale and design of the BiomarCaRE project.

Show MeSH
Related in: MedlinePlus